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Heme metabolism is central to blood-stage infection by the malaria parasite, Plasmodium48 
falciparum. Parasites retain a heme biosynthesis pathway but do not require its activity during 49 
infection of heme-rich erythrocytes, where they can scavenge host heme to meet metabolic 50 
needs. Nevertheless, heme biosynthesis in parasite-infected erythrocytes can be potently 51 
stimulated by exogenous 5-aminolevulinic acid (ALA), resulting in accumulation of the 52 
phototoxic intermediate, protoporphyrin IX (PPIX). Here we use photodynamic imaging, mass 53 
spectrometry, parasite gene disruption, and chemical probes to reveal that vestigial host enzymes 54 
in the cytoplasm of Plasmodium-infected erythrocytes contribute to ALA-stimulated heme 55 
biosynthesis and that ALA uptake depends on parasite-established permeability pathways. We 56 
show that PPIX accumulation in infected erythrocytes can be harnessed for antimalarial 57 
chemotherapy using luminol-based chemiluminescence and combinatorial stimulation by low-58 
dose artemisinin to photoactivate PPIX to produce cytotoxic reactive oxygen. This photodynamic 59 












 Malaria is an ancient and deadly scourge of humanity, with hundreds of millions of 71 
people infected by Plasmodium malaria parasites and more than 600,000 deaths each year.1 72 
Substantial progress has been made in reducing the global malaria burden, due in part to the 73 
success of artemisinin-based combination drug therapies (ACTs). Recent identification of 74 
artemisinin-tolerant parasites in southeast Asia, however, has raised concerns that the broad 75 
potency of ACTs against all parasite strains may be waning, which could lead to a resurgence in 76 
malaria deaths.2,3 These concerns motivate continued efforts to deepen understanding of basic 77 
parasite biology in order to identify new drug targets and facilitate development of novel 78 
therapies. 79 
 Heme is a ubiquitous biological cofactor required by nearly all organisms to carry out 80 
diverse redox biochemistry.4 Heme metabolism is a dominant feature during Plasmodium 81 
infection of erythrocytes, the most heme-rich cell in the human body and the stage of parasite 82 
development that causes all clinical symptoms of malaria. Parasites sequester and biomineralize 83 
the copious heme released during large-scale hemoglobin digestion in their acidic food 84 
vacuole,5,6 but they also require heme as a metabolic cofactor for cytochrome-mediated electron 85 
transfer within mitochondria.5-7  86 
Sequencing of the P. falciparum genome over a decade ago and subsequent studies have 87 
revealed that parasites encode and express all of the conserved enzymes for a complete heme 88 
biosynthesis pathway (Figure 1a), but the role and properties of this pathway have been the 89 
subject of considerable confusion and uncertainty.5,6,8 This pathway was originally proposed to 90 
be essential for blood-stage parasite development and thus a potential drug target,9 as host heme 91 
was thought to be inaccessible for parasite utilization in mitochondria. Recent studies, however, 92 
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have clarified that de novo heme synthesis is not required by intraerythrocytic parasites and 93 
therefore is unlikely to be a viable target for therapeutic inhibition.10,11 The parasite-encoded 94 
ferrochelatase (FC) can be knocked out to ablate heme biosynthesis but parasite growth is 95 
unaffected, suggesting that parasites can scavenge host heme to satisfy metabolic requirements 96 
during blood-stage infection.  97 
Here we use chemical and physical probes to decipher the role of upstream enzymes in 98 
heme biosynthesis by parasite-infected erythrocytes. Contrary to simple predictions, genetic 99 
disruption of the parasite porphobilinogen deaminase (PBGD) and coproporphyrinogen III 100 
oxidase (CPO) had no effect on the ability of Plasmodium-infected erythrocytes to convert 101 
exogenous ALA into heme, as monitored by mass spectrometry and photodynamic imaging of 102 
porphyrin intermediates. Biochemical fractionation revealed that vestigial host enzymes 103 
remaining in the erythrocyte cytoplasm contribute to ALA-stimulated heme biosynthesis, 104 
explaining why disruption of parasite enzymes had no effect on biosynthetic flux. We used 105 
small-molecule probes to show that ALA uptake by erythrocytes, which are normally 106 
impermeable to ALA, requires the parasite nutrient acquisition pathways established after 107 
invasion. Finally, we show that latent host enzyme activity can be exploited for antimalarial 108 
photodynamic therapy, using 1) ALA to stimulate production of phototoxic PPIX, 2) luminol-109 
based chemiluminescence to photoactivate PPIX cytotoxicity within infected erythrocytes, and 110 







Exogenous ALA stimulates heme biosynthesis and photosensitizes parasites. Production of 117 
5-aminolevulinic acid (ALA) by ALA synthase (ALAS) is the regulated step in heme 118 
biosynthesis. Exogenous ALA bypasses this step and stimulates biosynthetic flux, leading to 119 
accumulation of the final intermediate, protoporphyrin IX (PPIX), since conversion of PPIX to 120 
heme by ferrochelatase becomes rate limiting.12 PPIX is fluorescent (Figure 1- figure supplement 121 
1) and its cellular accumulation can be directly visualized by fluorescence microscopy, a 122 
phenomenon called photodynamic imaging that has been exploited for visualizing cancerous 123 
tumor boundaries during surgical resection.13  124 
 Prior work indicated that exogenous ALA stimulates PPIX production in P. falciparum 125 
parasites.10,14 We therefore posited that ALA treatment could serve as a probe of heme 126 
biosynthesis activity in Plasmodium-infected erythrocytes by enabling direct visualization of 127 
PPIX production and the cellular consequences of light activation. Untreated parasites imaged on 128 
an epifluorescence microscope display only background auto-fluorescence from hemozoin 129 
crystals in the parasite digestive vacuole (Figure 1b). Parasites grown in 200 µM ALA, however, 130 
display bright red fluorescence distributed throughout the infected erythrocyte, as expected for 131 
accumulation of PPIX (Figure 1b).  132 
 PPIX is also known to generate cytotoxic reactive oxygen species when photo-133 
illuminated, due to formation of an excited triplet state that can undergo collisional energy 134 
transfer with ground state triplet oxygen to produce highly reactive singlet oxygen.13 The ability 135 
to kill ALA-treated cells by light activation of accumulating PPIX has been exploited to 136 
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 The cytotoxic effects of light-activating PPIX were readily apparent by monitoring the 139 
motion of hemozoin crystals that dynamically tumble within the digestive vacuole of individual 140 
parasites.  Although the origin and physiological significance of this motion remain unknown, 141 
hemozoin dynamics serve as an internal biomarker of food vacuole integrity and parasite 142 
viability.5 Hemozoin motion in untreated parasites was unaffected by exposure to light that 143 
overlaps the excitation wavelength of PPIX (Videos 1 and 2). In contrast, the hemozoin 144 
dynamics in ALA-treated parasites were rapidly ablated by light (Videos 3 and 4). Ultra-145 
structural analysis by electron microscopy revealed a loss of electron density within the digestive 146 
vacuole of ALA-treated and illuminated parasites (Figure 1- figure supplement 2), suggesting 147 
disruption of the food vacuole membrane and outward diffusion of the vacuolar protein contents. 148 
These changes are consistent with a photodynamic mechanism of PPIX-mediated generation of 149 
reactive oxygen species that cause pleiotropic cytotoxic damage, including loss of lipid bilayer 150 
integrity.  151 
 To test the effects of these changes on bulk parasite culture, we monitored the growth of 152 
untreated versus ALA-treated parasites over several days with 2-minute daily exposures to 153 
broad-wavelength white light on an overhead projector light box. Whereas untreated parasite 154 
cultures grew normally in the presence of light, the growth of ALA-treated cultures was strongly 155 
attenuated by light (Figure 1c and Figure 1- figure supplement 3), consistent with a prior 156 
report.14 Microscopic examination by blood smear revealed that ALA-treated cultures 157 
predominantly contained karyolytic and pyknotic parasites (Figure 1- figure supplement 4), 158 
indicative of widespread cell death. The photosensitivity of parasite growth in ALA was fully 159 
rescued by 50 µM succinylacetone (SA), an ALA dehydratase (ALAD) inhibitor shown in 160 
previous work to substantially reduce PPIX biosynthesis from ALA in parasite-infected 161 
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erythrocytes.10,11 This chemical rescue confirmed that parasite photosensitivity in ALA requires 162 
biosynthetic conversion of ALA to PPIX. 163 
 164 
Stable disruption of parasite enzymes or the apicoplast organelle does not affect heme 165 
biosynthesis from ALA. The constituent enzymes of the parasite’s heme biosynthesis pathway 166 
are distributed between three sub-cellular compartments: the mitochondrion, the cytoplasm, and 167 
the chloroplast-like but non-photosynthetic apicoplast organelle (Figure 1a).6 Prior work 168 
indicated that the parasite ferrochelatase gene could be knocked out, resulting in a complete 169 
ablation of de novo heme synthesis but with no effect on parasite growth.10,11 This observation 170 
provided strong evidence that parasites do not require heme biosynthesis for growth in 171 
erythrocytes, where they can presumably scavenge abundant host heme to meet metabolic needs. 172 
We therefore reasoned that upstream enzymes in the parasite-encoded heme biosynthesis 173 
pathway should also be amenable to genetic disruption and that such ablations would block 174 
production of PPIX from exogenous ALA (Figure 1a) and thus prevent parasite photosensitivity. 175 
 We successfully disrupted the parasite genes encoding the apicoplast-targed 176 
porphobilinogen deaminase (PBGD) (Figure 2- figure supplement 1) and the cytosolic 177 
coproporphyrinogen III oxidase (CPO) (Figure 2- figure supplement 2), using single-crossover 178 
homologous recombination to truncate the open reading frame for each gene. Southern blot and 179 
PCR analysis confirmed correct integration and gene disruption in clonal parasite lines (Figure 2- 180 
figure supplements 3 and 4). Contrary to simple predictions, however, these genetic disruptions 181 
had no effect on the ability of parasite-infected erythrocytes to incorporate 13C-labelled ALA into 182 
heme, PPIX, or coproporphyrinogen III (Figure 2a), as monitored by a previously developed 183 
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liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay,10 and clonal growth of 184 
both parasite lines remained fully photosensitive in ALA (Figure 2b,c). 185 
 To further probe the functional contributions to heme biosynthesis by the parasite 186 
apicoplast and its constituent enzymes, we stably disrupted this organelle by treating parasites 187 
with doxycycline and isopentenyl pyrophosphate (IPP). Doxycycline inhibits the prokaryotic 188 
translation machinery of the apicoplast, which blocks replication of the small apicoplast genome, 189 
prevents organelle segregation, and results in unviable apicoplast-deficient parasite progeny.15 190 
The lethal effects of doxycycline, however, can be chemically rescued by IPP, which enables 191 
parasites to make essential isoprenoids despite apicoplast disruption and leads to a stable 192 
metabolic state in which parasites lack the intact organelle such that nuclear-encoded proteins 193 
ordinarily targeted to the apicoplast become stranded in small vesicles.16 We confirmed 194 
apicoplast loss in doxycycline and IPP-treated parasites by using microscopy to verify disrupted 195 
apicoplast targeting of the nuclear-encoded ALAD enzyme (Figure 2d and Figure 2- figure 196 
supplement 5), PCR to confirm loss of the small apicoplast genome (Figure 2- figure supplement 197 
6), and western blot to visualize disruption of post-translational processing of ALAD (Figure 2- 198 
figure supplement 7). Despite apicoplast disruption, these parasites retained their capacity for 199 
heme biosynthesis (Figure 2a) and remained fully photosensitive in ALA (Figure 2e). Together 200 
with the gene disruption results above, these observations strongly suggested that parasite-201 
infected erythrocytes have a parallel biosynthetic pathway that bypasses functional disruption of 202 
the parasite enzymes targeted to the apicoplast and cytoplasm.  203 
 204 
Erythrocytes retain vestigial heme biosynthesis enzymes with latent activity stimulated by 205 
ALA. The heme biosynthesis pathway in human cells is distributed between mitochondria and 206 
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the cytoplasm, with four cytosolic enzymes that correspond to the four apicoplast-targeted 207 
enzymes in Plasmodium parasites.4,6,17 During human erythropoiesis, precursor reticulocytes 208 
carry out prolific heme biosynthesis, but this activity is absent in mature erythrocytes due to loss 209 
of mitochondria and their constituent heme biosynthesis enzymes, including ALA synthase and 210 
ferrochelatase.17 Proteomic studies have confirmed that mature erythrocytes retain the cytosolic 211 
enzymes (ALAD, PBGD, UROS, and UROD),18,19 but this vestigial pathway is ordinarily 212 
quiescent due to the lack of ALA synthesis or uptake in erythrocytes. We hypothesized that 213 
exogenous ALA taken up by parasite-infected erythrocytes might stimulate the latent activity of 214 
these cytosolic human enzymes, resulting in biosynthetic flux through this truncated host 215 
pathway and production of downstream tetrapyrrole intermediates that could be taken up by the 216 
parasite via hemoglobin import or other mechanisms and converted into heme within the parasite 217 
mitochondrion.  218 
The cytosolic human enzymes remaining in the mature erythrocyte would be expected to 219 
produce coproporphyrinogen III (CPP) from ALA.  Our observation that disruption of the 220 
parasite CPO had no effect on conversion of ALA into heme by intraerythrocytic parasites 221 
suggests that a soluble fraction of human CPO, which is thought to be predominantly targeted to 222 
the mitochondrial intermembrane space (IMS),6,17 persists in the erythrocyte cytoplasm after 223 
maturation of precursor reticulocytes and mitochondrial loss. Indeed, other mitochondrial IMS 224 
proteins, such as cytochrome c, are known to partition into the cytoplasm under certain 225 
conditions.20,21 CPO catalyzes production of protoporphyrinogen IX, which in the oxygen-rich 226 
environment of erythrocytes can spontaneously oxidize to form protoporphyrin IX.22 227 
 In support of this model, we noted that red porphyrin fluorescence in ALA-treated 228 
infected erythrocytes was not limited to the parasite but was detectable throughout the 229 
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erythrocyte cytoplasm (Figure 1b), as expected for host enzyme activity and production of PPIX 230 
in this compartment. To directly test the model that enzymes remaining in the erythrocyte 231 
cytoplasm could catalyze PPIX biosynthesis from ALA, we permeabilized uninfected 232 
erythrocytes using the detergent saponin, clarified lysates by centrifugation followed by sterile 233 
filtration, and then used LC-MS/MS to monitor heme and porphyrin biosynthesis from 5-[13C4]-234 
ALA added to the filtered lysate supernatant. We detected formation of 13C-labelled PPIX and 235 
CPP but not heme, and this biosynthetic activity was fully blocked by succinylacetone (Figure 236 
3a). These observations provide direct support for our model that erythrocytes retain a vestigial 237 
and partial biosynthesis pathway capable of converting exogenous ALA into PPIX but unable to 238 
convert PPIX to heme due to lack of mitochondria and ferrochelatase.  239 
 240 
ALA uptake by erythrocytes requires new permeability pathways established by 241 
Plasmodium infection. In contrast to parasite-infected erythrocytes, uninfected erythrocytes 242 
showed no detectable porphyrin fluorescence in the presence of ALA (Figure 3b), consistent 243 
with reports that the erythrocyte membrane has a low permeability to amino acids.23-25 244 
Electroporation of uninfected erythrocytes in the presence of ALA, however, resulted in robust 245 
intracellular porphyrin fluorescence (Figure 3b), supporting our model that host enzymes have 246 
latent biosynthetic activity that requires a mechanism for ALA uptake across the normally 247 
impermeable erythrocyte membrane. 248 
 Upon invasion, Plasmodium parasites export hundreds of effector proteins into host 249 
erythrocytes. These proteins dramatically alter the architecture of the infected erythrocyte and 250 
establish new permeability pathways (NPP) that enhance host cell uptake of amino acids and 251 
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other nutrients from host serum.26 We hypothesized that selective uptake of ALA by parasite-252 
infected erythrocytes was mediated by NPP mechanisms.  253 
To test this model, we utilized a recently published parasite line in which the export of 254 
parasite proteins into host erythrocytes, including establishment of nutrient permeability 255 
pathways, can be conditionally regulated with the synthetic small-molecule ligand trimethoprim 256 
(TMP).27 In these parasites, protein export and NPP mechanisms are functional in the presence of 257 
TMP but are blocked in its absence. We maintained or washed out TMP from a synchronized 258 
culture of late schizonts, allowed parasites to rupture and reinvade new erythrocytes, and then 259 
incubated both sets of parasites in ALA for 8 hours. Whereas TMP-treated parasites with normal 260 
protein export and permeability displayed robust PPIX fluorescence indistinguishable from that 261 
of wild-type parasites, parasites incubated without TMP showed no detectable PPIX fluorescence 262 
(Figure 3c). We observed similar results in wild-type parasites using the small-molecule drug 263 
furosemide, which blocks parasite-derived NPP mechanisms directly (Figure 3- figure 264 
supplement 1).28 We conclude that ALA is selectively taken up by infected erythrocytes via 265 
parasite-dependent nutrient acquisition pathways and metabolized to PPIX by vestigial host 266 
enzymes within the erythrocyte cytoplasm (Figure 4). 267 
 268 
Plasmodium-encoded heme biosynthesis pathway has no detectable activity during blood-269 
stage infection. Our observation that disruption of the parasite-encoded PBGD and CPO does 270 
not affect biosynthetic production of heme and PPIX from ALA suggests that host enzyme 271 
activity in the erythrocyte cytoplasm provides the dominant contribution to PPIX biosynthesis in 272 
ALA-treated intraerythrocytic parasites. To dissect these parallel pathways and test whether the 273 
parasite pathway alone, in the absence of host enzymes, can support heme biosynthesis from 274 
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ALA, we fractionated parasite-infected erythrocytes using saponin to selectively permeabilize 275 
host cell membranes while leaving parasite membranes intact (Figure 5a). Under these 276 
conditions, soluble erythrocyte proteins can be washed away to leave the intact live parasite 277 
natively embedded within the resulting erythrocyte ghost (Figure 5b,c). Parasites treated in this 278 
fashion remain metabolically active for 5-6 hours or longer, retain a membrane potential, 279 
accumulate fluorescent dyes such a mitotracker red (Figure 5b,c), and carry out DNA 280 
synthesis.29,30 After saponin treatment and washout, we placed parasites back into culture 281 
medium containing 13C-ALA and incubated them overnight before extracting them for analysis 282 
by LC-MS/MS. We failed to detect biosynthesis of heme, PPIX, or CPP in fractionated asexual 283 
and sexual blood-stage parasites (Figure 5d), suggesting that the apicoplast-localized portion of 284 
the parasite heme biosynthesis pathway is largely or completely inactive during blood-stage 285 
infection.  286 
To test this conclusion within undisrupted parasites, we created a transgenic parasite line 287 
expressing an apicoplast-targeted version of the uroporphyrinogen III methyltransferase (cobA) 288 
protein from Propionibacterium freudenreichii to serve as a biosensor of heme biosynthesis 289 
pathway activity within the parasite apicoplast. The cobA protein catalyzes conversion of the 290 
heme biosynthesis intermediate uroporphyrinogen III into the red fluorescent products 291 
sirohydrochlorin and trimethylpyrrocorphin (Figure 6a) and has been shown to function when 292 
heterologously expressed in bacteria (Figure 6b), yeast, and mammalian cells.31,32 We targeted a 293 
cobA-GFP fusion protein to the apicoplast in ALA-treated parasites (Figure 6c) but were unable 294 
to detect any red fluorescence in this organelle indicative of cobA-mediated conversion of 295 
uroporphyrinogen III to the fluorescent products, suggesting that parasite enzymes targeted to 296 
this organelle are inactive in both asexual and sexual blood stages (Figure 6d,e). We also noted 297 
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that growth of ∆FC parasites,10 which would be expected to accumulate PPIX during native 298 
pathway activity (Figure 1a), was insensitive to light in the absence of ALA (Figure 6- figure 299 
supplement 1). These observations suggest that heme biosynthesis in blood-stage P. falciparum 300 
parasites is only operative when exogenous ALA is present to stimulate PPIX production by 301 
remnant host enzymes in the erythrocyte cytoplasm, with subsequent PPIX uptake and 302 
conversion to heme by ferrochelatase in the parasite mitochondrion (Figure 4). 303 
 304 
Development of chemiluminescence-based photodynamic therapy for treatment of blood-305 
stage malaria. Our results and those of prior studies suggested that stimulation of heme 306 
biosynthesis might be exploited for antimalarial photodynamic therapy (PDT). Conventional 307 
PDT requires an external light source to photoactivate and kill ALA-stimulated cells.13,33,34 308 
While such approaches can successfully target localized shallow-tissue tumors,13,34 they are 309 
impractical for treating malaria due to the dispersed nature of blood-stage infection, the 310 
sequestration of mature P. falciparum parasites along the vascular endothelium, and the 311 
requirement to illuminate every infected erythrocyte. 312 
 To bypass the need for external light, chemiluminescence has been proposed as an 313 
alternative means to photoactivate the cytotoxicity of PPIX in ALA-stimulated cells. Trial 314 
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intraerythrocytic parasites might show heightened susceptibility to chemiluminescence-based 320 
photodynamic therapy (CL-PDT) (Figure 6a).  321 
 To test the efficacy of a CL-PDT strategy for targeting blood-stage P. falciparum, we 322 
incubated intraerythrocytic parasites with twice-daily media changes in combinatorial treatments 323 
of ALA, luminol, and 4-iodophenol, a small-molecule that has been shown to enhance the 324 
intensity and duration of luminol chemiluminescence.38 Parasites treated with optimized 325 
concentrations each compound in single or double combination showed little effect on parasite 326 
growth (Figure 7- figure supplement 2). The combination of all three compounds, however, 327 
potently inhibited parasite growth (Figure 6b), and microscopic examination by blood-smear 328 
revealed widespread parasite death (Figure 7- figure supplement 3). The growth effects of this 329 
combination could be fully rescued by succinylacetone (Figure 6b), supporting a photodynamic 330 
mechanism requiring PPIX biosynthesis from ALA and and enhanced chemiluminescence by 331 
luminol. 332 
 The development of parasite resistance to frontline antimalarial drugs continues to 333 
hamper malaria treatment and eradication efforts worldwide. To test whether a CL-PDT 334 
mechanism remains effective against parasites with diverse resistance to distinct drugs, we 335 
turned to studies with Dd2 parasites, which have multidrug resistance to antifolate and quinolone 336 
antibiotics,39 and a clinical isolate containing a kelch-13 protein mutation that confers 337 
artemisinin tolerance.2 In both parasite lines, combination treatment with ALA, luminol, and 4-338 
iodophenol potently ablated parasite growth (Figure 7- figure supplement 4).  339 
 Artemesinin and its derivatives are current frontline drugs used for treatment of malaria, 340 
usually in combination with a partner drug. Artemisinin, whose endoperoxide moiety is 341 
reductively cleaved by intracellular iron to generate reactive oxygen radicals,40 has been shown 342 
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to potently stimulate luminol chemiluminescence in vitro,41 suggesting the possibility of 343 
combining CL-PDT with artemisinin for antimalarial treatment. To test the efficacy of an 344 
artemisinin-enhanced CL-PDT strategy, we incubated 3D7 parasites with twice-daily media 345 
changes in ALA, luminol, and sub-therapeutic doses (500 pM, 10% of EC50, Figure 7- figure 346 
supplement 5) of dihydroartemisinin (DHA). Single and double combinations had little effect 347 
(Figure 7- figure supplement 6), but all three compounds together potently ablated parasite 348 
growth, and growth inhibition could be fully rescued with succinylacetone (Figure 6c).  349 
 350 
Discussion 351 
 Malaria parasites, like nearly all other organisms, have a metabolic requirement for 352 
heme.5-7 Despite access to abundant host heme during intraerythrocytic infection, parasites retain 353 
a complete heme biosynthesis pathway that was regarded for two decades as essential and a 354 
potential drug target.9 Our work and recent studies have now successfully disrupted four of the 355 
eight pathway enzymes, providing firm evidence that de novo heme synthesis is dispensable 356 
during blood-stage infection. These data strongly suggest that parasites have mechanisms to 357 
scavenge host heme to meet metabolic needs and clarify that heme biosynthesis is not a viable 358 
target for classical drug inhibition.10,11  359 
Our results further suggest that the parasite pathway is not active during intraerythrocytic 360 
infection. This inactivity may reflect the low availability of the succinyl-CoA precursor due to 361 
limited TCA cycle flux42 and additional regulatory mechanisms, such as feedback inhibition by 362 
host heme or active site inhibition by endogenous metabolites,43 that suppress the activity of 363 
apicoplast-targeted enzymes during blood-stage parasite development. The functional quiescence 364 
of this specific biosynthetic pathway, despite expression of the constituent enzymes, may reflect 365 
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a general survival strategy and adaptation by parasites to closely match metabolic requirements 366 
with nutritional availability within specific host environments, such as previously described for 367 
parasite acquisition of fatty acids.44 Indeed, prior studies suggest that the parasite heme synthesis 368 
pathway is required for development within the mosquito and human liver,10,11 host 369 
environments with lower heme availability compared to erythrocytes and in which parasite heme 370 
requirements appear to be elevated due to enhanced reliance on mitochondrial electron transport 371 
for ATP synthesis.5,6,45 A prior study also reported that blood-stage P. falciparum parasites adopt 372 
distinct physiological states in vivo, including a state with heightened oxidative metabolism and 373 
mitochondrial activity that may arise during host starvation.46 It remains a future challenge to test 374 
whether heme biosynthesis by the parasite-encoded pathway can be stimulated by host 375 
nutritional status during intraerythrocytic infection. 376 
 Despite the dispensable nature and apparent inactivity of the parasite-encoded heme 377 
biosynthesis pathway, infected erythrocytes retain a paradoxical ability to synthesize heme from 378 
exogenous ALA. This biosynthetic activity requires the Plasmodium ferrochelatase but not the 379 
upstream enzymes in the parasite pathway. Indeed, knock-out of the Plasmodium FC prevented 380 
conversion of PPIX to heme,10 but our disruption of the parasite PBGD and CPO genes, as well 381 
as the entire apicoplast organelle, had no effect on ALA-stimulated heme synthesis (Figure 2). 382 
Our work resolves this paradox by identifying a latent contribution to heme biosynthesis in 383 
parasite-infected erythrocytes from vestigial host enzymes remaining in the erythrocyte 384 
cytoplasm.  Since erythrocytes lack mitochondria, they are missing the initial and terminal 385 
pathway enzymes, cannot synthesize ALA, and thus retain only a truncated and normally 386 
inactive heme synthesis pathway. Analytical studies have reported that human serum contains 387 
0.1-0.2 µM ALA,47 but the low permeability of the erythrocyte membrane to ALA means that 388 
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extracellular ALA is largely inaccessible to vestigial host enzymes within uninfected 389 
erythrocytes.  390 
Our study clarifies that NPP mechanisms of parasite-infected red blood cells enable 391 
efficient uptake of exogenous ALA, which can be metabolized by vestigial human enzymes 392 
within the oxygen-rich erythrocyte cytoplasm to produce PPIX that can be converted to heme by 393 
FC within the parasite mitochondrion (Fig. 4). Thus, the 0.2 µM ALA natively present in human 394 
serum may be sufficient to stimulate low-level heme biosynthesis within parasites in vivo. 395 
Indeed, we detect 13C-labeled PPIX in parasites grown in 1 µM 5-[13C4]-ALA in vitro (Figure 4- 396 
figure supplementary 1), supporting a model that serum ALA stimulates heme biosynthesis 397 
during malaria infection in vivo. Such activity, however, is not required to support blood-stage 398 
parasite growth. We note that prior work suggested a role for remnant host enzymes in heme 399 
biosynthesis by malaria parasites, but this proposal differed by positing that human enzymes 400 
such as ALAD were somehow imported and active within the parasite cytoplasm.48  401 
The ability to photosensitize parasites with exogenous ALA and then kill them with light 402 
introduces exciting possibilities for developing new photodynamic treatment strategies, 403 
exemplifies how deep understanding of fundamental parasite metabolism can be leveraged for 404 
designing novel therapies, and highlights that non-essential pathways can still serve as 405 
therapeutic targets. We have shown that luminol-based chemiluminescence, when stimulated by 406 
combinatorial delivery of low-dose 4-iodophenol or artemisinin, can circumvent the 407 
conventional PDT requirement for external light and potently ablate parasite growth (Figure 6). 408 
We note that ALA, luminol, and DHA have excellent toxicity profiles, favorable 409 
pharmacokinetic properties, and have each been used clinically.34,49-52 These results suggest the 410 
possibility of including ALA and luminol with therapeutic doses of artemisinin (or its clinical 411 
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derivatives) as a novel form of artemisinin combination therapy for treating malaria. Multidrug-412 
resistant parasites remain susceptible to this photodynamic strategy, which relies on host enzyme 413 
activity outside the genetic control of parasites and thus is refractory to development of 414 
resistance-conferring mutations. This strategy may also be effective against other 415 
intraerythrocytic parasites, such as Babesia. As for any new therapy suggested by in vitro studies, 416 
additional in vivo experiments will be required to optimize treatment regimens for our proposed 417 
therapy and to confirm efficacy and safety. 418 
Finally, we note that this strategy of using artemisinin to stimulate intracellular light 419 
emission by luminol for ALA-based photodynamic therapy may be applicable to treating deep-420 
tissue cancers, for which poor accessibility to external light also limits current PDT approaches 421 
in development for cancer therapy.13 Artemisinin has shown promising anti-cancer properties on 422 
its own,53 and thus its combination with ALA and luminol may provide potent synergy for cancer 423 
chemotherapy. 424 
 425 
Materials and Methods 426 
Materials. All reagents were of the highest purity commercially available. Succinylacetone, 5-427 
aminolevulinic acid, 4-iodophenol, trimethoprim, furosemide, saponin, isopentenyl 428 
pyrophosphate, doxycycline, luminol, and dihydroartemisinin were purchased from Sigma. 5-429 
[13C4]-aminolevulinic acid was purchased from Cambridge Isotope Laboratories, Inc. 430 
 431 
Microscopy. Images of live or fixed parasites were acquired on an Axio Imager.M1 432 
epifluorescence microscope (Carl Zeiss Microimaging, Inc.) equipped with a Hamamatsu 433 
ORCA-ER digital CCD camera and running Axiovision 4.8 software, as described previously.54 434 
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Live parasite nuclei were stained with 5 µM Hoechst 3342 added immediately prior to image 435 
acquisition. For photodynamic imaging studies, parasites were cultured in 200-500 µM ALA in 436 
the absence or presence of 50 µM succinylacetone for 6-12 hours prior to visualization. 437 
Hemozoin movement in parasite digestive vacuoles was imaged by acquiring 10-20 sequential 438 
frames at 1 second intervals on the bright-field channel. Images were cropped and superimposed 439 
in Adobe Photoshop and exported as movie files with a 0.1 second frame delay. 440 
Immunofluorescence images were acquired by fixing and staining parasites as previously 441 
described.55,56 Electron microscopy images of parasites subjected to light or 500 µM ALA + light 442 
were obtained as previously described.27 Uninfected erythrocytes were washed and resuspended 443 
in 1X cytomix containing 500 µM ALA, electroporated in a manner identical to parasite 444 
transfections (see below), washed in PBS, incubated overnight at 37˚ C, and imaged as described 445 
above for live parasites. Images acquired on different channels for common samples were 446 
processed with identical brightness and contrast settings. 447 
 448 
Parasite growth analysis. Parasite growth was monitored by diluting asynchronous parasites to 449 
0.5% parasitemia and allowing culture expansion with daily or twice daily media changes. 450 
Parasitemia was measured daily by diluting 10 µl of each resuspended culture in 200 µl acridine 451 
orange (1.5 µg/ml) and analyzing by flow cytometry, as previously described.57 To assess the 452 
light sensitivity of ALA-treated parasites, asynchronous parasites were cultured in 200µM ALA 453 
in the absence or presence of 50 µM succinylacetone and subjected to 2 minute daily exposures 454 
to broad wavelength white light on an overhead projector. Daily parasitemia measurements were 455 
plotted as a function of time and fit to an exponential growth equation using GraphPad Prism 5.0. 456 
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 For chemiluminescence experiments, asynchronous parasites were diluted to 0.5% 457 
parasitemia and incubated ±100 µM ALA and ±50 µM succinylacetone for 8 hours. After 8 458 
hours, parasite media was changed to also include 750 µM luminol, 50 µM 4-iodophenol, and 459 
0.5 nM dihydroartemisinin in the indicated combinations. Parasite cultures were allowed to 460 
expand over 5 days, with twice-daily (7 am and 4 pm) media changes in the indicated 461 
combinations. Parasitemia was measured daily on replicate samples, as indicated above. 462 
Experiments were performed using 3D7 (drug sensitive) parasites, Dd2 (multidrug resistant) 463 
parasites39, and a clinical isolate2 (MRA-1241) bearing the I543T mutation in the Kelch-13 gene 464 
locus responsible for artemisinin tolerance. Exposure of parasite cultures to ambient light was 465 
minimized by changing media within darkened TC hoods and covering parasite culture dishes 466 
during brief (5-10 sec.) transits to and from incubators. The effect of 100 µM ALA on parasite 467 
growth varied slightly between experiments, possibly due to differences between distinct batches 468 
of donated erythrocytes. 469 
 For IC50 determinations, asynchronous parasites were diluted to 1% parasitemia and 470 
incubated with variable drug concentrations for 48 hours without media change. After 48 hours, 471 
parasitemia was determined in duplicate samples for each drug concentration, normalized to the 472 
parasitemia in the absence of drug, plotted as a function of the log of the drug concentration, and 473 
fit to a sigmoidal growth inhibition curve using GraphPad Prism 5.0. 474 
 475 
Parasite strains, culture, genetic modification, and transgene expression. Parasite culture and 476 
transfection were performed in RPMI supplemented with Albumax, as previously described.54 477 
Cloning was performed using either restriction endonuclease digestion and ligation or the In-478 
Fusion system (Clontech).  479 
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For episomal expression of P. falciparum ALA dehydratase (PF3D7_1440300) and 480 
coproporphyrinogen III oxidase (CPO, PF3D7_1142400) fused to a C-terminal GFP tag (ALAD-481 
GFP and CPO-GFP), cDNA inserts encoding the complete ALAD and CPO genes (exons only) 482 
were RT-PCR-amplified from total parasite RNA using the Superscript III system (Life 483 
Technologies) and primers CACTATAGAACTCGAGATGTTAAAATCAGATGTA 484 
GTGCTTTTATTGTATATAC and CTGCACCTGGCCTAGGTAGAGTTAATTCTATATT 485 
AAAATTATTATTTGAATTATCATC (ALAD) or ACGATTTTTTCTCGAGATGAAA 486 
GATGAGATAGCTCCTAATGAATATTTTAGAAATTTATG and CTGCACCTGGCCT 487 
AGGGTAGTCCACCCACTTTTTGGGATAC (CPO), digested with XhoI/AvrII, and ligated 488 
into the XhoI/AvrII sites of a digested pTEOE vector that was identical to a previously described 489 
pTyEOE vector27 except that the pTEOE plasmid contained human DHFR in place of yeast 490 
DHOD as the positive selection marker. Plasmid-based expression of the ALAD-GFP fusion was 491 
driven by the HSP86 promoter. This plasmid (50 µg) was co-transfected into 3D7 parasites along 492 
with plasmid pHTH (10 µg) for transient expression of the piggyback transposase that mediates 493 
integration of the pTEOE plasmid into the parasite genome.58 Parasites were selected with 5 nM 494 
WR99210. 495 
For episomal expression of Propionibacterium freudenreichii (shermanii) 496 
uroporphyrinogen III methyltransferase (cobA) (Genbank: CBL55989.1) targeted to the parasite 497 
apicoplast, the cobA gene was PCR-amplified from plasmid pISA41731 using the primers 498 
ACGATTTTTTCTCGAGATGACCACCACACTGTTGCCCGGCACTGTC and CTGCACCT 499 
GGCCTAGGGTGGTCGCTGGGCGCGCGATGG, digested with XhoI/AvrII, and ligated into 500 
the XhoI/AvrII-cut pTEOE vector described above. An insert encoding the P. falciparum acyl 501 
carrier protein (ACP) leader sequence (residues 1-60) with 5’- and 3’- XhoI sites, previously 502 
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PCR-amplified from parasite cDNA,54 was digested with XhoI and ligated into the XhoI-cut 503 
cobA/pTEOE vector to generate an in-frame ACPL-cobA-GFP fusion gene. This plasmid was co-504 
transfected with pHTH into 3D7 parasites as described above. 505 
For disruption of the P. falciparum genes encoding PBGD (PF3D7_1209600) and CPO 506 
(PF3D7_1142400), primer pairs (PBGD: CACTATAGAACTCGAGGATCATAATAA 507 
TGATACATTATGTACTATTGGGACATCGTCC and CTGCACCTGGCCTAGGAA 508 
CTGCTATAATGCCTTGACCTAAGGCAGGATAAATCAGG; CPO: CACTATAG 509 
AACTCGAGTTTTTTCAAATATTTATAAAAACAGGAAAAAAGAAGAAAAAATA and 510 
CTGCACCTGGCCTAGGATAACATTTACAATCCTTATTATTATTATTATTATTGTTG 511 
ATGG) were used to PCR-amplify 360 bp and 471 bp sequences from the middle of the 1.3 kb 512 
PBGD and 1.6 kb CPO genes, respectively. These inserts were cloned by In-Fusion into the 513 
XhoI/AvrII sites of the pPM2GT vector,59 which encodes a C-terminal GFP tag after the AvrII 514 
site and also contains a human DHFR marker for positive selection with 5 nM WR99210. This 515 
vector was further modified to introduce a 2A peptide sequence60 followed by the yeast 516 
dihydroorotate dehydrogenase (yDHOD) sequence61, after the 3’ end of the GFP cassette, to 517 
enable positive selection for integration with the parasite DHOD inhibitor, DSM1. The yDHOD 518 
marker, however, was not used for selection in this study, and use of this GFP-2A-519 
yDHPD/PM2GT vector for positive selection of plasmid integration into the genome will be 520 
described elsewhere. Plasmids (50 µg) were transfected into 3D7 parasites by electroporation. 521 
Parasites were subjected to three rounds of positive selection with 5 nM WR99210. After the 522 
first and second selections, cultures were maintained for three weeks in the absence of drug 523 
pressure prior to the subsequent round of positive selection. After the third round of positive 524 
selection, parasites were cloned by limiting dilution. Clonal parasites that had integrated the 525 
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plasmid at the desired locus to disrupt the target genes by single cross-over homologous 526 
recombination were verified by PCR and Southern blot, as previously described,59 and retained 527 
for further analysis. 528 
To introduce a C-terminal GFP tag into the endogenous locus of the P. falciparum PBGD 529 
gene (PF3D7_1209600), primer pairs CACTATAGAACTCGAGGATCATAATAA 530 
TGATACATTATGTACTATTGGGACATCGTCC and CTGCACCTGGCCTAGGTTTATTA 531 
TTTAAAAGGTGCAATTCAGCCTCCGCTTTTATTTTG were used to PCR-amplify the 532 
complete PBGD coding sequence. This insert was cloned by In-Fusion into the 2A-533 
yDHOD/PM2GT vector described above and transfected into 3D7 parasites by electroporation as 534 
above. Stable integration was achieved after three rounds of positive selection in WR99210, and 535 
clones were isolated by limiting dilution and verified by PCR and southern blot. 536 
∆FC D10 parasites, described in a prior study10, were obtained from Akhil Vaidya 537 
(Drexel University) and were cultured as described above, including two-minute daily exposures 538 
to broad-wavelength white light using an overhead projector light box. 539 
For apicoplast disruption experiments, parasites were cultured in 1 µM doxycycline and 540 
200 µM IPP for 7-21 days.16 After 7 days, genomic DNA was harvested and analyzed by PCR 541 
for the nuclear-encoded acyl carrier protein (ACP) gene (primers 542 
ATGAAGATCTTATTACTTTGTATAATTTTTC and TTTTAAAGAGCTAGATGGGTTTTT 543 
ATTTTTTATC) and apicoplast-encoded rps8 (primers ATGATTATTAAATTTTTAAATAATG 544 
and TTACAAAATATAAAATAATAAAATACC) and ORF91 (primers ATGACTTT 545 
ATATTTAAATAAAAATTT and TTACATATTTTTTTTATTGAAGAACG) genes to confirm 546 
selective loss of the apicoplast genome. 547 
 548 
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selective loss of the apicoplast genome. 547 
 548 
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Gametocyte Induction and Culturing. 3D7 ∆PM1 (plasmepsin 1) parasites62 and 3D7 parasites 549 
expressing ACPleader-cobA-GFP from a TEOE plasmid (described above) were synchronized 550 
using 5% sorbitol and cultured using gentamycin-free media. Gametocytogenesis was stress-551 
induced in mid-trophozoite parasites (5-7% parasitemia) by increasing hematocrit to 4% (by 552 
removing half of the culture medium volume) for 12 hours. Parasites were maintained in culture 553 
for 4-6 days, at which point mostly stage III-IV gametocytes were visible. ACPleader-cobA-GFP 554 
gametocytes were incubated overnight in the presence or absence of 500 µM ALA and imaged 555 
by live parasite microscopy as described above. For 13C-ALA labeling experiments, gametocytes 556 
were passaged over a magnetic column to remove uninfected erythrocytes and concentrate the 557 
gametocyte-infected cells, lysed in 0.02% saponin (0.2-µM filtered), placed back into culture 558 
medium containing 200 µM 5-[13C4]-ALA, and incubated overnight at 37˚ C. Parasites were then 559 
isolated by centrifugation, extracted, and analyzed by tandem mass spectroscopy as described 560 
below. 561 
 562 
Analysis of heme biosynthesis by 13C-labeling and liquid chromatography-tandem mass 563 
spectrometry (LC-MS/MS). Parasites were cultured in 200 µM 5-[13C4]-ALA for 12-24 hours, 564 
harvested by centrifugation, lysed in 0.05% cold saponin, washed in PBS, and extracted with 565 
DMSO. Deuteroporphyrin was added as an internal standard, and extracts were analyzed for 13C-566 
labeled heme, PPIX, and CPPIII using a previously published LC-MS/MS assay.10 Detection of 567 
coproporphyrin III (CPPIII) serves as a biomarker for detecting coproporphyrinogen III, which is 568 
rapidly oxidized to CPPIII upon exposure to air during cell lysis and extraction.22 569 
 570 
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Fractionation of parasite-infected erythrocytes. To assess whether parasites could synthesize 571 
heme from ALA in the absence of host enzymes in the erythrocyte cytoplasm, parasite-infected 572 
red blood cells were lysed with 0.05% saponin (0.2 µM filtered), spun briefly (3 min., 850 x g) to 573 
pellet, washed in PBS, and resupended in 12 ml of RPMI/albumax growth media supplemented 574 
with 200 µM 5-[13C4]-ALA. Parasites were incubated over-night at 37˚ C, harvested by 575 
centrifugation, and extracted and analyzed by tandem mass spectrometry as described above. 576 
 577 
Preparation of lysates from uninfected erythrocytes. To assess the heme biosynthesis capacity 578 
of the erythrocyte cytoplasm, 500 µl packed red blood cells (described previously54) were lysed 579 
in 20 ml of 0.04% saponin/PBS (0.2 µM filtered) and centrifuged at 25,000 x g for 60 minutes to 580 
pellet unlysed cells and any organelles. The superficial 15 ml of the lysate supernatant was 581 
removed and 0.2 µM filtered, supplemented with 200 µM 5-[13C4]-ALA in the absence or 582 
presence of 50 µM succinylacetone, incubated overnight at 37˚ C, and analyzed by tandem mass 583 
spectrometry as described above. 584 
 585 
Chemical block of parasite nutrient uptake pathways. The 3D7 parasite line expressing the 586 
endogenous HSP101 from its genomic locus and bearing a C-terminal E. coli DHFR degradation 587 
domain (DDD) fusion tag was previously published.27 To test whether ALA-uptake by parasite-588 
infected erythrocytes depends on parasite-established nutrient acquisition pathways in the host 589 
cell membrane, we split a synchronous culture of HSP101-DDD into two populations of late 590 
schizonts (purified over a magnetic column) and washed out trimethoprim (TMP) from one of 591 
the two cultures. Both cultures (±TMP) were permitted to lyse and reinvade fresh erythrocytes 592 
overnight. The following morning, parasites were placed in 200 µM ALA as early rings, 593 
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incubated for 8 hours at 37˚ C, and imaged by live parasite microscopy as described above. 594 
Alternatively, asynchronous wild-type 3D7 parasites were incubated in the absence or presence 595 
of 100 µM furosemide for one hour to block nutrient acquisition pathways, followed by addition 596 
of 500 µM ALA and further incubation for eight hours. Parasites were then imaged by live 597 
parasite microscopy as described above. 598 
 599 
Antibodies and Live Cell Stains. The following antibodies were used for immunofluorescence 600 
(IFM) and western blot (WB) analysis at the indicated dilutions: goat anti-GFP (Abcam 5450) 601 
(IFM 1:500, WB 1:1000), rabbit anti-ACP56,63 (IFM: 1:500), Alexa Fluor 488-conjugated 602 
chicken anti-goat (IFM: 1:500), Alexa Fluor 555-conjugated donkey anti-rabbit (IFM: 1:500), 603 
donkey anti-goat- IRDye 800 (Licor Biosciences) (WB: 1:10,000). Mitotracker Red was used at 604 
50 nM final concentration and was added to parasite cultures 30 minutes prior to harvest and 605 
analysis. 606 
 607 
Absorbance and Luminescence Spectroscopy. Fluorescence excitation and emission spectra of 608 
pure PPIX in aqueous solution (excitation 400 nm, emission 620 nm) and of clarified lysates of 609 
E. coli bacteria expressing cobA (excitation 360 nm, emission 600 nm) and chemiluminescence 610 
spectra of luminol were obtained on a Cary Eclipse fluorescence spectrophotometer (Varian, 611 
Inc.) in either fluorescence or luminescence mode using 10-nm slit widths and a PMT detector 612 
voltage setting of 600. Luminol solutions contained 25 mM luminol in 100 mM NaOH (aq) to 613 
which 0.1% (w/v) ammonium persulfate (aq) was added to stimulate light emission. 614 
 615 
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Imaging hemozoin dynamics in parasite digestive vacuole. Time-lapse bright field images of 616 
parasites were acquired with 1 sec. delays, composed into movie files using Adobe Photoshop, 617 
and played back with 0.1 sec. delays between frames. Bright field images were acquired before 618 
and after 4 sec. image acquisitions with the Zeiss filter sets 38 (excitation 450-490 nm) and 43 619 
HE (excitation 537-562 nm). 620 
 621 
Homology Models. Homology models of PBGD and CPO were generated using the Swiss-622 
Model interface on the Expasy website (http://swissmodel.expasy.org). The template structures 623 
for modeling were human PBGD (PBD: 3EQ1) and human CPO (PDB: 2AEX). 624 
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microscopy images of untreated and 200 µM ALA-treated parasites. Fluorescence images were 806 
acquired with a Zeiss filter set 43 HE (excitation 537-562 nm, emission 570-640 nm). (c) Growth 807 
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of asynchronous 3D7 parasites in the presence or absence of 200 µM ALA and 50 µM 808 
succinylacetone (SA), with 2-minute exposures to white light on an overhead projector on days 809 
0-2. Parasitemia (percentage of total erythrocytes infected with parasites) as a function of time 810 
was fit with an exponential growth equation. 811 
 812 
Figure 2. Heme biosynthesis in infected erythrocytes persists despite disruption of parasite 813 
enzymes or the apicoplast. (a) LC-MS/MS detection of 13C-labelled heme, PPIX, and CPP in 814 
parasites grown in 200 µM 5-[13C4]-ALA. Parasites were extracted in DMSO, supplemented 815 
with deuteroporphyrin as an internal standard, and analyzed by LC-MS/MS. Integrated analyte 816 
peak areas were normalized to PPIX in each sample. RBC: uninfected red blood cells, WT: 817 
parental clone 3D7, IPP/dox: isopentenyl pyrophosphate/doxycycline-treated 3D7 parasites. (b-818 
c) Growth of asynchronous ∆PBGD (b) and ∆CPO (c) 3D7 parasites in the presence or absence 819 
of 200 µM ALA, with 2-minute light exposures on an overhead projector on days 0-2. WT 820 
growth was fit to an exponential equation. (d) Bright field and fluorescence images of live 3D7 821 
parasites expressing ALAD-GFP from a plasmid before or after two-week treatment with IPP 822 
and doxycycline. (e) Growth of asynchronous IPP/doxycycline-treated parasites in the presence 823 
or absence of 200 µM ALA and 50 µM succinylacetone (SA), with 2-minute light exposures on 824 
an overhead projector on days 0-2. 825 
 826 
Figure 3. Erythrocytes have latent porphyrin biosynthesis activity that requires exogenous 827 
ALA and parasite permeability mechanisms to enable ALA uptake. (a) LC-MS/MS 828 
detection of 13C-labelled PPIX and CPP in erythrocyte lysate supernatants incubated with 200 829 
µM 5-[13C4]-ALA without or with 50 µM succinylacetone (SA). Erythrocytes were lysed in 830 
 33
0.04% saponin, centrifuged at 25,000 x g for 60 min., and 0.2 µM syringe filtered prior to ALA 831 
addition. (b) Bright field and fluorescence (Zeiss filter set 43 HE) images of uninfected 832 
erythrocytes incubated in 500 µM ALA before or after electroporation. (c) Bright field and 833 
fluorescence images of parasites cultured in 500 µM ALA with normal (+TMP) or blocked (-834 
TMP) establishment of parasite permeability pathways in the erythrocyte membrane. Infected 835 
erythrocyte permeability was modulated using a 3D7 parasite line expressing HSP101 tagged at 836 
its endogenous locus with a trimethoprim (TMP)-dependent destabilization domain.27 TMP was 837 
maintained or washed out from synchronous schizont-stage parasites, which were allowed to 838 
rupture and invade new erythrocytes. 500 µM ALA was added to both cultures after invasion, 839 
and parasites were imaged 8 hours later. 840 
 841 
Figure 4. Schematic depiction of ALA-uptake and porphyrin biosynthesis pathways in 842 
Plasmodium-infected erythrocytes. For simplicity, all membranes are depicted as single. 843 
Porphyrins synthesized in the infected erythrocyte cytoplasm from exogenous ALA may be 844 
transported across the parasite membrane via unspecified mechanisms or may be taken up via 845 
hemoglobin import mechanisms. Succinylacetone (SA) inhibits ALAD and blocks porphyrin 846 
synthesis from ALA. 847 
 848 
Figure 5. Analysis of heme biosynthesis activity in parasite-infected erythrocytes after 849 
saponin permeabilization and culture in 13C-labelled ALA. (a) Parasite-infected erythrocytes 850 
were permeabilized in 0.02% saponin, washed to remove the erythrocyte cytoplasm, and placed 851 
back into culture medium containing 200 µM 5-[13C4]-ALA for 12 hours prior to DMSO 852 
extraction and analysis by LC-MS/MS. Bright field and fluorescence image of live (b) asexual 853 
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Figure 5. Analysis of heme biosynthesis activity in parasite-infected erythrocytes after 849 
saponin permeabilization and culture in 13C-labelled ALA. (a) Parasite-infected erythrocytes 850 
were permeabilized in 0.02% saponin, washed to remove the erythrocyte cytoplasm, and placed 851 
back into culture medium containing 200 µM 5-[13C4]-ALA for 12 hours prior to DMSO 852 
extraction and analysis by LC-MS/MS. Bright field and fluorescence image of live (b) asexual 853 
 34
trophozoite and (c) stage IV sexual gametocyte treated with 0.02% saponin and stained with 20 854 
nM Mitotracker Red. (d) LC-MS/MS quantification of 13C-labelled heme, PPIX, and CPP in 855 
DMSO extracts of intact WT 3D7 asexual parasites, saponin-released asexual parasites, and 856 
saponin-released gametocytes cultured overnight in 200 µM 5-[13C4]-ALA.  857 
 858 
Figure 6. Analysis of heme biosynthetic flux within the apicoplast of live parasites using the 859 
cobA biosensor. (a) Fluorescence excitation (black) and emission (red) spectra of clarified 860 
lysates from E. coli bacteria expressing the cobA gene from Propionibacterium freudenreichii 861 
(shermanii), showing the expected peaks for conversion of uroporphyrinogen III to 862 
sirohydrochlorin and trimethylpyrrocorphin. (b) Fluorescence microscopy images of live bacteria 863 
expressing the cobA gene, acquired on the bright field and red (Zeiss filter set 43 HE) channels. 864 
(c) Immunofluorescence images of fixed 3D7 parasites episomally expressing an ACPleader-865 
cobA-GFP fusion confirm targeting to the parasite apicoplast. Parasites were stained with αGFP 866 
and αACP (acyl carrier protein, apicoplast marker). The αACP antibody recognizes an epitope 867 
that is different from the ACP leader sequence. (d) Fluorescence microscopy images of live 868 
asexual parasites episomally expressing ACPleader-cobA-GFP without or with 500 µM exogenous 869 
ALA. (e) Fluorescence microscopy images of live stage III-IV sexual gametocytes episomally 870 
expressing ACPleader-cobA-GFP without or with 500 µM exogenous ALA. Fluorescence images 871 
in (d) and (e) were acquired on the GFP (Zeiss filter set 38) and red (Zeiss filter set 43 HE) 872 
channels. 873 
 874 
Figure 7. Targeting blood-stage Plasmodium parasites by chemiluminescence-based 875 
photodynamic therapy (CL-PDT). (a) Schematic depiction of a CL-PDT mechanism for 876 
 35
targeting blood-stage malaria. (b) Effect of 100 µM ALA, 750 µM luminol (lum), 50 µM 4-877 
iodophenol (ph), 50 µM succinylacetone (SA) and their combination (all 0.25% DMSO) on the 878 
growth of asynchronous 3D7 parasites. (c) Effect of 100 µM ALA, 750 µM luminol, 0.5 nM 879 
dihydroartemisinin (DHA), 50 µM succinylacetone (SA) and their combination (all 0.25% 880 
DMSO) on the growth of asynchronous 3D7 parasites. Parasite media was changed twice daily, 881 
and parasitemia increases were fit to an exponential growth equation. 882 
 883 
Video Titles and Legends 884 
Video 1. Hemozoin dynamics in the digestive vacuole of untreated parasites prior to 4-sec. 885 
acquisitions with the Zeiss filter sets 38 (excitation 450-490 nm) and 43 HE (excitation 537-886 
562 nm). Time-lapse bright field images were acquired with 1 sec. delays and played back with 887 
0.1 sec. delays between frames. 888 
 889 
Video 2. Hemozoin dynamics in the digestive vacuole of untreated parasites are unaffected 890 
by 4-sec. acquisitions with the Zeiss filter sets 38 (excitation 450-490 nm) and 43 HE 891 
(excitation 537-562 nm). Time-lapse bright field images were acquired with 1 sec. delays and 892 
played back with 0.1 sec. delays between frames. Bright field images were acquired before and 893 
after 4 sec. image acquisitions with the Zeiss filter sets 38 (excitation 450-490 nm) and 43 HE 894 
(excitation 537-562 nm). 895 
 896 
Video 3. Hemozoin dynamics in the digestive vacuole of 200 µM ALA-treated parasites 897 
prior to 4-sec. acquisitions with the Zeiss filter sets 38 (excitation 450-490 nm) and 43 HE 898 
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(excitation 537-562 nm). Time-lapse bright field images were acquired with 1 sec. delays and 899 
played back with 0.1 sec. delays between frames. 900 
 901 
Video 4. Hemozoin dynamics in the digestive vacuole of 200 µM ALA-treated parasites are 902 
ablated after 4-sec. acquisitions with the Zeiss filter sets 38 (excitation 450-490 nm) and 43 903 
HE (excitation 537-562 nm). Time-lapse bright field images were acquired with 1 sec. delays 904 
and played back with 0.1 sec. delays between frames. Bright field images were acquired before 905 
and after 4 sec. image acquisitions with the Zeiss filter sets 38 (excitation 450-490 nm) and 43 906 
HE (excitation 537-562 nm). 907 
 908 
Figure Supplement Titles and Legends 909 
Figure 1- figure supplement 1. Fluorescence excitation and emission spectrum of 910 
protoporphyrin IX in aqueous buffer.  911 
 912 
Figure 1- figure supplement 2. Transmission electron microscopy images of untreated and 913 
500 µM ALA-treated P. falciparum-infected erythrocytes after light exposure on an 914 
overhead projector light box. The white arrow identifies the digestive vacuole. Scale bar equals 915 
1 µm.  916 
 917 
Figure 1- figure supplement 3. ALA-dose dependence of photosensitivity by blood-stage 918 
Plasmodium parasites. Asynchronous parasites were cultured in the indicated concentration of 919 
ALA and exposed to 2 min. light daily. Parasitemia was measured after 48 hours and normalized 920 
to a reference culture grown without ALA. 921 
 37
 922 
Figure 1- figure supplement 4. Giemsa-stained blood smear of P. falciparum culture after 923 
three days of treatment with 200 µM ALA and 2-min. daily light exposure on an overhead 924 
projector light box. Black arrows identify dead parasite remnants. 925 
 926 
Figure 2- figure supplement 1. Immunofluorescence images of fixed 3D7 parasites 927 
expressing full-length PBGD tagged at its endogenous locus with C-terminal GFP confirm 928 
targeting of the native protein to the parasite apicoplast. Parasites were stained with αGFP 929 
and αACP (acyl carrier protein, apicoplast marker). 930 
 931 
Figure 2- figure supplement 2.  Fluorescence microscopy images of live 3D7 parasites 932 
episomally expressing full-length CPO with a C-terminal GFP tag confirm protein 933 
localization to the parasite cytoplasm. 934 
 935 
Figure 2- figure supplement 3. Disruption of the P. falciparum porphobilinogen deaminase 936 
(PBGD) gene (PF3D7_1209600) by single-crossover homologous recombination. (a) 937 
Schematic depiction of the PBGD gene locus before and after incorporation of the donor plasmid 938 
via single-crossover recombination. Red arrows indicate the primers used to selectively PCR-939 
amplify either the intact WT or disrupted ∆PBGD locus. SacI and BglII were used to digest the 940 
donor plasmid and gDNA of WT and ∆PBGD parasites to give the expected fragment sizes 941 
indicated in parentheses for hybridization to a PBGD bp 601-960 oligonucleotide probe. (b) PCR 942 
analysis of gDNA from WT and ∆PBGD clones using the primers indicated in (a) to selectively 943 
amplify the 1.3 kb WT gene or the 960 bp truncated gene. (c) Southern blot analysis of gDNA 944 
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Figure 2- figure supplement 3. Disruption of the P. falciparum porphobilinogen deaminase 936 
(PBGD) gene (PF3D7_1209600) by single-crossover homologous recombination. (a) 937 
Schematic depiction of the PBGD gene locus before and after incorporation of the donor plasmid 938 
via single-crossover recombination. Red arrows indicate the primers used to selectively PCR-939 
amplify either the intact WT or disrupted ∆PBGD locus. SacI and BglII were used to digest the 940 
donor plasmid and gDNA of WT and ∆PBGD parasites to give the expected fragment sizes 941 
indicated in parentheses for hybridization to a PBGD bp 601-960 oligonucleotide probe. (b) PCR 942 
analysis of gDNA from WT and ∆PBGD clones using the primers indicated in (a) to selectively 943 
amplify the 1.3 kb WT gene or the 960 bp truncated gene. (c) Southern blot analysis of gDNA 944 
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from 3D7 WT and ∆PBGD clonal parasites after digestion with SacI and BglII, hybridization 945 
with a PBGD bp 601-960 oligonucleotide probe, and detection using the Amersham AlkPhos 946 
Labeling and CDP-Star Chemiluminescent reagents. (d) Homology model of P. falciparum 947 
PBGD (human PBGD template structure 3EQ1) to indicate the portion of the protein retained 948 
(cyan) or lost (green) by single-crossover truncation. The deleted sequence comprises half of the 949 
active site binding pocket, identified by the dipyrromethane cofactor shown in red. 950 
 951 
Figure 2- figure supplement 4. Disruption of the P. falciparum coproporphyrinogen III 952 
oxidase (CPO) gene (PF3D7_1142400) by single-crossover homologous recombination. (a) 953 
Schematic depiction of the CPO gene locus before and after incorporation of the donor plasmid 954 
via single-crossover recombination. Red arrows indicate the primers used to selectively PCR-955 
amplify either the intact WT or disrupted ∆CPO locus. XhoI and KpnI were used to digest the 956 
donor plasmid and gDNA of WT and ∆CPO parasites to give the expected fragment sizes 957 
indicated in parentheses for hybridization to a CPO bp 610-1080 oligonucleotide probe. (b) PCR 958 
analysis of gDNA from WT and ∆CPO clones using the primers indicated in (a) to selectively 959 
amplify the 1.6 kb WT gene or the 1.1 kb truncated gene. (c) Southern blot analysis of gDNA 960 
from 3D7 WT and ∆CPO clonal parasites after digestion with XhoI and KpnI, hybridization with 961 
a CPO bp 610-1080 oligonucleotide probe, and detection using the Amersham AlkPhos Labeling 962 
and CDP-Star Chemiluminescent reagents. (d) Homology model of P. falciparum CPO (human 963 
CPO template structure 2AEX) to indicate the portion of the protein retained (blue) or lost 964 
(green) by single-crossover truncation. The deleted sequence comprises half of the active site 965 
binding pocket, identified by the citrate molecule shown in red. 966 
 967 
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Figure 2- figure supplement 5. Immunofluorescence images of fixed 3D7 parasites 968 
expressing full-length ALAD tagged at its endogenous locus with C-terminal GFP confirm 969 
targeting to the parasite apicoplast. Parasites were stained with αGFP and αACP (acyl carrier 970 
protein, apicoplast marker). 971 
 972 
Figure 2- figure supplement 6. PCR analysis of genomic DNA from untreated WT parasites 973 
or parasites cultures ≥7 days in 1 µM doxycycline and 200 µM isopentenylpyrophosphate 974 
(IPP). ACPL refers to the 385 bp leader sequence (with introns) of the nuclear-encoded acyl 975 
carrier protein. Rps8 (387 bp) and ORF91 (276) are two genes encoded by the Plasmodium 976 
apicoplast genome. 977 
 978 
Figure 2- figure supplement 7. Western blot analysis of parasites episomally expressing 979 
ALAD-GFP and cultured 7 days in IPP and doxycycline. Blots confirm disrupted proteolytic 980 
processing of the ALAD leader sequence that results in retarded migration by SDS-PAGE 981 
relative to parasites cultured in normal conditions. Extracts from WT and IPP/doxycycline 982 
parasites were loaded separately in lanes 2 and 5, respectively, and were loaded together in lanes 983 
3 and 4.  984 
 985 
Figure 3- figure supplement 1. Furosemide blocks ALA uptake and PPIX biosynthesis in 986 
parasite-infected erythrocytes. Asynchronous wild-type 3D7 parasites were incubated in the 987 
absence or presence of 100 µM furosemide for one hour to block nutrient acquisition pathways, 988 
followed by addition of 500 µM ALA and further incubation for eight hours. Parasites were then 989 
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Figure 3- figure supplement 1. Furosemide blocks ALA uptake and PPIX biosynthesis in 986 
parasite-infected erythrocytes. Asynchronous wild-type 3D7 parasites were incubated in the 987 
absence or presence of 100 µM furosemide for one hour to block nutrient acquisition pathways, 988 
followed by addition of 500 µM ALA and further incubation for eight hours. Parasites were then 989 
 40
imaged by live microscopy on the bright field or red fluorescence (Zeiss filter set 43 HE) 990 
channels. In lower panel, parasite nuclei (blue) were visualized with Hoechst DNA stain. 991 
 992 
Figure 4- figure supplement 1. Growth of parasites in 1 µM 5-[13C4]-ALA results in 993 
detectable biosynthesis of 13C-labeled PPIX. Parasites were grown overnight in 1 µM 5-[13C4]-994 
ALA, permeabilized with saponin, extracted in DMSO, and analyzed by LC-MS/MS for 13C-995 
labeled heme, PPIX, and CPP. Integrated peak areas measured for each analyze were normalized 996 
to that measured for the deuteroporphyrin internal standard added to each sample. 997 
 998 
Figure 6- figure supplement 1. Disruption of the ferrochelatase gene in ∆FC parasites does 999 
not photosensitize parasites. WT or ∆FC D10 parasites were cultured under normal growth 1000 
conditions (without exogenous ALA) with two-minute light exposures on an overhead projector 1001 
light box on days 0-2. Culture parasitemia as a function of time was fit to an exponential growth 1002 
model. Both WT and ∆FC parasites had parasitemia doubling times of 1.1 days under these 1003 
conditions. 1004 
 1005 
Figure 7- figure supplement 1. Spectral compatibility of luminol and PPIX. (a) Overlay of 1006 
normalized absorbance spectrum of PPIX (black) and chemiluminescence spectrum of luminol 1007 
(red). (b) Chemiluminescence of luminol (solid red) is attenuated in the presence of PPIX (solid 1008 
black), giving rise to a difference spectrum (dashed black) that is similar to the absorbance 1009 
spectrum of PPIX in the spectral region that overlaps luminol chemiluminescence. Solutions 1010 
contained 25 mM luminol in 100 mM NaOH (aq), 0.5% (w/v) ammonium persulfate, and/or 70 1011 
µM PPIX. 1012 
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 1013 
Figure 7- figure supplement 2. Effect of combinatorial ALA, luminol, and 4-iodophenol on 1014 
parasite growth. (a) Luminol concentrations as high as 750 µM (in 0.2% DMSO) have no effect 1015 
on 3D7 parasite growth over 48 hours. (b) Effect of 750 µM luminol, 100 µM ALA, and their 1016 
combination (all in 0.2% DMSO) on the growth of asynchronous 3D7 parasites. (c) 1017 
Concentration dependence of growth inhibition of 3D7 parasites by 4-iodophenol (in 0.2% 1018 
DMSO) over 48 hours. (d) Effect of 100 µM ALA, 50 µM 4-iodophenol, and their combination 1019 
(all in 0.2% DMSO) on the growth of asynchronous 3D7 parasites. 1020 
 1021 
Figure 7- figure supplement 3. Giemsa-stained blood smear of 3D7 parasite culture after 3 1022 
days of treatment in 100 µM ALA, 750 µM luminol, and 50 µM 4-iodophenol. Arrows point 1023 
to dead parasite remnants. 1024 
 1025 
Figure 7- figure supplement 4. Efficacy of chemiluminescence-based photodynamic therapy 1026 
with drug-resistant parasites. Effect of 100 µM ALA, 750 µM luminol, 50 µM 4-iodophenol, 1027 
50 µM succinylacetone (all 0.2% DMSO) and their combination on the growth of asynchronous 1028 
(a) Dd2 parasites or (b) Kelch-13 I543T (MRA-1241) parasites. 1029 
 1030 
Figure 7- figure supplement 5. Concentration dependence of growth inhibition of 3D7 1031 
parasites by dihydroartemisinin (DHA) over 48 hours (in 0.2% DMSO). 1032 
 1033 
Figure 7- figure supplement 6. Effect of 500 pM DHA, 100 µM ALA, and their combination 1034 
(all in 0.2% DMSO) on the growth of asynchronous 3D7 parasites. 1035 
 41
 1013 
Figure 7- figure supplement 2. Effect of combinatorial ALA, luminol, and 4-iodophenol on 1014 
parasite growth. (a) Luminol concentrations as high as 750 µM (in 0.2% DMSO) have no effect 1015 
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combination (all in 0.2% DMSO) on the growth of asynchronous 3D7 parasites. (c) 1017 
Concentration dependence of growth inhibition of 3D7 parasites by 4-iodophenol (in 0.2% 1018 
DMSO) over 48 hours. (d) Effect of 100 µM ALA, 50 µM 4-iodophenol, and their combination 1019 
(all in 0.2% DMSO) on the growth of asynchronous 3D7 parasites. 1020 
 1021 
Figure 7- figure supplement 3. Giemsa-stained blood smear of 3D7 parasite culture after 3 1022 
days of treatment in 100 µM ALA, 750 µM luminol, and 50 µM 4-iodophenol. Arrows point 1023 
to dead parasite remnants. 1024 
 1025 
Figure 7- figure supplement 4. Efficacy of chemiluminescence-based photodynamic therapy 1026 
with drug-resistant parasites. Effect of 100 µM ALA, 750 µM luminol, 50 µM 4-iodophenol, 1027 
50 µM succinylacetone (all 0.2% DMSO) and their combination on the growth of asynchronous 1028 
(a) Dd2 parasites or (b) Kelch-13 I543T (MRA-1241) parasites. 1029 
 1030 
Figure 7- figure supplement 5. Concentration dependence of growth inhibition of 3D7 1031 
parasites by dihydroartemisinin (DHA) over 48 hours (in 0.2% DMSO). 1032 
 1033 
Figure 7- figure supplement 6. Effect of 500 pM DHA, 100 µM ALA, and their combination 1034 
(all in 0.2% DMSO) on the growth of asynchronous 3D7 parasites. 1035 






